Skip to main content

Anthony M. DeMaio

ML Strategies - Vice President of Government Relations

[email protected]

+1.202.434.7386

Share:

Anthony is a Vice President on ML Strategies’ federal advocacy team in Washington, DC. He works with clients to develop and implement effective messaging and legislative strategy. Anthony helps clients navigate the Congress and administration in pursuit of policy objectives and federal funding, as well as through congressional inquiries.

For well over a decade, Anthony has been working with Congress, the bureaucracy, and the media to advance client interests. He has represented major multi-national corporations, start-ups, non-profit organizations, industry coalitions, and labor unions from most major sectors of the economy. Anthony works extensively in health care, both reimbursement and regulation. He also represents clients in transportation, infrastructure, defense, technology, and manufacturing on issues including taxation, trade, and federal appropriations.

Prior to joining ML Strategies, Anthony served in government affairs and public relations roles at firms in Washington and Boston. He is active in Democratic politics, particularly in his home state of Massachusetts.

viewpoints

New Biden Executive Order Emphasizes Women’s Health

March 27, 2024 | Alert | By Pamela Mejia, Anthony DeMaio

Read more

ARPA-H Commits $100 Million to Accelerate Women’s Health Research through Sprint for Women’s Health

February 28, 2024 | Alert | By Pamela Mejia, Sarah C. Palmer, Anthony DeMaio

Read more

Post-Election 2022: A Look into the Next Congress

November 22, 2022 | Blog | By Anthony DeMaio, Pamela Mejia

Read more

Look Ahead: Upcoming Congressional Work Period – July 2022

July 11, 2022 | Blog | By Alexander Hecht, Christian Tamotsu Fjeld, Anthony DeMaio, R. Neal Martin, Pamela Mejia

The next three weeks will be full of activity in Washington D.C., as the House of Representatives and Senate are working to push their legislative agendas to garner support from their constituents ahead of an August recess and before political “silly season” officially kicks in ahead of the upcoming mid-term elections in November. Here’s our latest update on what you can expect in Congress during the July work period.
Read more
Anyone who has spent any time around health care policymaking circles in Washington, D.C. has heard about the intense five-year cycle Congress goes through in order to reauthorize the biggest user fee programs at the Food and Drug Administration (FDA). Mintz previously published this wonderful explanation of the process complete with an estimated timeline for how this year’s reauthorization was likely to go. As a reminder, the current authorization for FDA’s various human product user fee programs – with the exception of the over-the-counter drug program that was freshly created in 2020 – will expire on September 30, 2022 with the end of the federal government’s fiscal year, unless they are renewed by Congress before that time.
Read more

Massachusetts for ARPA-H

May 3, 2022 | Blog | By Anthony DeMaio

Read more

House Democrats Weigh Major Tax Changes for Businesses, Funds, and Individuals

October 12, 2021 | Alert | By Gregg M. Benson, Anthony DeMaio

Read about the U.S. House Ways and Means Committee’s proposed tax legislation intended to partially fund the $3.5 trillion Build Back Better Act to fund Democratic priorities.
Read more
The second half of 2021 will be a busy stretch for Congress. In addition to the typical must-pass legislation, Democrats controlling both chambers and the White House are committed to several big spending bills, too. This preview is a rundown of these bills, what’s included in them, and how we can expect them to play out.
Read more
Since the Democrats reclaimed control of the House of Representatives in 2018, barrels of ink have been spilled on the topic of “congressionally-directed spending”. Better known as earmarks, this funding mechanism allows Members of Congress to send money directly to projects identified in their districts, largely bypassing the federal bureaucracy and its protracted grant application process. For more than a decade, the Congress has banned the practice of including congressionally-directed funding in spending bills. Now, Democrats in control of both chambers and the White House are poised to bring earmarks back. On March 17th, House Republicans voted to reverse the GOP Conference’s ten year-old ban on congressionally directed spending, paving the way for Members from both parties to make requests in upcoming spending and infrastructure bills.
Read more

Webinar Recording: FDA in 2021: A Look Ahead

February 18, 2021 | Webinar | By Joanne Hawana, Anthony DeMaio

In this fireside discussion, Mintz attorney Joanne Hawana and Aaron Josephson and Anthony DeMaio from ML Strategies explored policy activities that will likely have the greatest impact on stakeholders in 2021, and how the new Administration may impact the FDA in the year ahead and beyond.
Read more
Read less

News & Press

News Thumbnail
In an article published by The Boston Globe, Director of Government Relations at ML Strategies Anthony DeMaio was quoted in response to the Senate’s recent confirmation of Boston Mayor Martin J. Walsh as Secretary of the Department of Labor. In addition to pandemic response, Mr. DeMaio emphasized the importance of Walsh working to restore credibility and confidence in the department, particularly in enforcement.
Read less

Events & Speaking

Speaker
May
5
2021

Health Care Policy: Hot Topics in 2021

Women Business Leaders of the U.S. Health Care Industry Foundation (WBL)

Webinar

Webinar Reference Image
Moderator
Feb
18
2021

FDA in 2021: A Look Ahead

Mintz & ML Strategies

Webinar

Webinar Reference Image
Read less

Involvement

  • Board Member, Massachusetts Society of Washington, DC
Read less

Anthony M. DeMaio

ML Strategies - Vice President of Government Relations

Washington, DC